Jaffetilchin Investment Partners LLC lowered its position in Masimo Co. (NASDAQ:MASI) by 2.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,549 shares of the medical equipment provider’s stock after selling 184 shares during the quarter. Jaffetilchin Investment Partners LLC’s holdings in Masimo were worth $1,044,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently modified their holdings of the company. Claybrook Capital LLC bought a new position in Masimo in the fourth quarter worth $25,000. West Oak Capital LLC bought a new position in Masimo in the first quarter worth $28,000. Quantamental Technologies LLC bought a new position in Masimo in the fourth quarter worth $43,000. Financial Gravity Companies Inc. bought a new position in Masimo in the fourth quarter worth $49,000. Finally, FinTrust Capital Advisors LLC bought a new position in Masimo in the first quarter worth $61,000. 83.03% of the stock is owned by institutional investors and hedge funds.
NASDAQ:MASI traded up $1.30 during trading hours on Monday, reaching $150.12. The stock had a trading volume of 676,800 shares, compared to its average volume of 444,206. The company has a market capitalization of $7.99 billion, a PE ratio of 49.54, a PEG ratio of 2.97 and a beta of 1.14. The company’s 50 day moving average price is $140.75. Masimo Co. has a 52 week low of $96.14 and a 52 week high of $150.75.
MASI has been the topic of a number of recent research reports. BTIG Research cut Masimo from a “buy” rating to a “neutral” rating and set a $134.50 target price on the stock. in a research note on Tuesday, April 16th. Zacks Investment Research raised Masimo from a “hold” rating to a “buy” rating and set a $153.00 target price on the stock in a research note on Wednesday, May 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $155.00 price objective (up from $148.00) on shares of Masimo in a research report on Wednesday, March 13th. Piper Jaffray Companies increased their price objective on Masimo from $148.00 to $160.00 in a research report on Friday, May 17th. Finally, UBS Group increased their price objective on Masimo from $147.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $154.25.
In other Masimo news, EVP Anand Sampath sold 30,000 shares of Masimo stock in a transaction on Friday, June 14th. The stock was sold at an average price of $142.39, for a total transaction of $4,271,700.00. Following the completion of the sale, the executive vice president now directly owns 27,518 shares of the company’s stock, valued at approximately $3,918,288.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Yongsam Lee sold 258 shares of Masimo stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $145.00, for a total value of $37,410.00. Following the sale, the executive vice president now directly owns 73,736 shares of the company’s stock, valued at $10,691,720. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 76,242 shares of company stock valued at $10,846,053. 11.50% of the stock is owned by company insiders.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Recommended Story: Holder of Record
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.